Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab in Relapsed/Refractory CD38 Positive T-cell ALL (GMALL-Isatuximab)
NCT06648889Phase 2Recruiting
- Sponsor
- Goethe University Frankfurt
- Start
- Oct 2024
- Primary completion
- Jun 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Goethe University Frankfurt. Started Oct 2024; status: recruiting.
02
Drugs
isatuximab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT06648889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06648889.